|1.||Agbaria, Riad: 6 articles (01/2007 - 06/2002)|
|2.||Marquez, Victor E: 5 articles (09/2006 - 06/2002)|
|3.||Smee, Donald F: 4 articles (01/2008 - 01/2007)|
|4.||Johns, David G: 4 articles (05/2005 - 06/2002)|
|5.||Rahman, Aquilur: 3 articles (02/2015 - 11/2007)|
|6.||Ford, Harry: 3 articles (05/2005 - 06/2002)|
|7.||Glazer, Robert I: 2 articles (02/2015 - 11/2007)|
|8.||Quenelle, Debra C: 2 articles (01/2011 - 04/2006)|
|9.||Hurst, Brett L: 2 articles (01/2008 - 11/2007)|
|10.||Sidwell, Robert W: 2 articles (11/2007 - 01/2007)|
01/01/2011 - "Efficacy of orally administered low dose N-methanocarbathymidine against lethal herpes simplex virus type-2 infections of mice."
01/01/2007 - "Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice."
01/01/2011 - "N-MCT provided significant protection from mortality even when treatments were delayed until 3 days after viral infection. "
11/01/2007 - "(N)-MCT could be further pursued for its potential to treat orthopoxvirus infections in humans."
11/01/2007 - "route with (N)-MCT (100 mg/(kg day)) reduced lung, nasal, and brain virus titers during an IHD virus infection, but not nearly to the same extent as i.p. "
|2.||Herpesviridae Infections (Herpesvirus Infection)
|3.||Herpes Genitalis (Genital Herpes)
11/01/2002 - "The objective of the present study was to assess the pharmacokinetic profile of (N)-MCT in C57BL/6 mice bearing nontransduced MC38 and MC38/HSV-tk tumors. "
06/01/2002 - "In studies in vivo, both (N)-MCT and GCV (100 mg/kg) given twice daily for 7 days completely inhibited the growth of HSV-tk-transduced MC38 tumors while exhibiting no effect on nontransduced MC38 tumors in mice. "
09/01/2006 - "N-MCT given twice daily (100 mg/kg) for 7 days completely inhibited the growth of MC38 tumors derived from cells that express HSV-tk in mice while exhibiting no effect on tumors derived from non-transduced cells. "
09/01/2006 - "Tumor cells that are not responsive to antiviral therapy became sensitive to N-MCT if the cells expressed HSV-tk. "
11/01/2002 - "These results are essential for the future development and in postulating the most efficient use of (N)-MCT in the HSV-tk enzyme prodrug system for gene therapy approaches for the treatment of cancer."
|6.||triphosphoric acid (triphosphate)
|7.||Conditioned Culture Media
|9.||RNA (Ribonucleic Acid)